This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
zacks-consensus-estimate: Archive
Bitfarms Ltd. (BITF) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Bitfarms (BITF) delivered earnings and revenue surprises of -100.00% and -4.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
BITFNegative Net Change ALYAFNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Earnings Estimates Rising for Xometry (XMTR): Will It Gain?
by Zacks Equity Research
Xometry (XMTR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
XMTRPositive Net Change
earnings earnings-estimates earnings-estimates-revisions price-performance stock-performance zacks-consensus-estimate zacks-rank
Why Vitesse (VTS) Might be Well Poised for a Surge
by Zacks Equity Research
Vitesse Energy (VTS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
VTSNegative Net Change
earnings earnings-estimates earnings-estimates-revisions price-performance stock-performance zacks-consensus-estimate zacks-rank
Why Clear Secure (YOU) Might be Well Poised for a Surge
by Zacks Equity Research
Clear Secure (YOU) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
YOUNegative Net Change
earnings earnings-estimates earnings-estimates-revisions price-performance stock-performance zacks-consensus-estimate zacks-rank
Earnings Estimates Rising for AppLovin (APP): Will It Gain?
by Zacks Equity Research
AppLovin (APP) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
APPPositive Net Change
earnings earnings-estimates earnings-estimates-revisions price-performance stock-performance zacks-consensus-estimate zacks-rank
Earnings Estimates Rising for Enerflex (EFXT): Will It Gain?
by Zacks Equity Research
Enerflex (EFXT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
EFXTNegative Net Change
earnings earnings-estimates earnings-estimates-revisions price-performance stock-performance zacks-consensus-estimate zacks-rank
Can Remitly Global (RELY) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Remitly Global, Inc. (RELY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
RELYNegative Net Change
earnings earnings-estimates earnings-estimates-revisions price-performance stock-performance zacks-consensus-estimate zacks-rank
Why VAREX IMAGING (VREX) Might be Well Poised for a Surge
by Zacks Equity Research
VAREX IMAGING (VREX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
VREXPositive Net Change
earnings earnings-estimates earnings-estimates-revisions price-performance stock-performance zacks-consensus-estimate zacks-rank
Will Smucker (SJM) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Smucker (SJM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
SJMNegative Net Change
earnings earnings-beat earnings-esp earnings-estimates earnings-streak zacks-consensus-estimate
BioLife Solutions (BLFS) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
BioLife Solutions (BLFS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BLFSNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Adicet Bio (ACET) Upgraded to Buy: Here's Why
by Zacks Equity Research
Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ACETPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Relay Therapeutics (RLAY) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Relay Therapeutics (RLAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
RLAYPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Grand Canyon Education (LOPE) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Grand Canyon Education (LOPE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
LOPEPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Xeris Biopharma (XERS) Upgraded to Buy: Here's Why
by Zacks Equity Research
Xeris Biopharma (XERS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
XERSPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
All You Need to Know About Verona Pharma (VRNA) Rating Upgrade to Buy
by Zacks Equity Research
Verona Pharma (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
VRNANo Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
ITT (ITT) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
ITT (ITT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ITTNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
All You Need to Know About Howmet (HWM) Rating Upgrade to Strong Buy
by Zacks Equity Research
Howmet (HWM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
HWMNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Dorman Products (DORM) Upgraded to Buy: Here's Why
by Zacks Equity Research
Dorman Products (DORM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
DORMNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Global Partners (GLP) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Global Partners (GLP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
GLPNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Auna S.A. (AUNA) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Auna S.A. (AUNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AUNANegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
PagSeguro Digital Ltd. (PAGS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
PagSeguro Digital (PAGS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PAGSPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Amer Sports, Inc. (AS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Amer Sports, Inc. (AS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ASPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Home Depot (HD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Home Depot (HD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HDNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Viking Holdings (VIK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Viking (VIK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VIKPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Does U.S. Physical Therapy (USPH) Have the Potential to Rally 26.48% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 26.5% in U.S. Physical Therapy (USPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
USPHNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate